Abstract
There is conflicting evidence regarding the effect of endothelin-1 (ET-1) on platelets. Some studies show that ET-1 activates platelets, others show platelet inhibition with ET-1 and some studies did not detect an effect of ET-1. These conflicting results may be due to complex interactions between platelet ETA and ETB receptors. ET-1 antagonism may emerge as an important therapeutic strategy in the management of several vascular disorders. However, to date the only prescribed ET-1 antagonist is bosentan for pulmonary arterial hypertension. Bosentan is a dual ET- 1 antagonist (i.e. it acts on both ETA and ETB receptors). Whether this action involves an effect on platelets remains to be established. In this review some of the studies describing the effect of ET-1 on human platelets are discussed. Vascular diseases where ET-1 is implicated are also considered.
Keywords: endothelin, platelet, bosentan, pulmonary hypertension, vascular disease
Current Vascular Pharmacology
Title: Endothelin-1 and Human Platelets
Volume: 3 Issue: 4
Author(s): I. Anita Jagroop, Stella S. Daskalopoulou and Dimitri P. Mikhailidis
Affiliation:
Keywords: endothelin, platelet, bosentan, pulmonary hypertension, vascular disease
Abstract: There is conflicting evidence regarding the effect of endothelin-1 (ET-1) on platelets. Some studies show that ET-1 activates platelets, others show platelet inhibition with ET-1 and some studies did not detect an effect of ET-1. These conflicting results may be due to complex interactions between platelet ETA and ETB receptors. ET-1 antagonism may emerge as an important therapeutic strategy in the management of several vascular disorders. However, to date the only prescribed ET-1 antagonist is bosentan for pulmonary arterial hypertension. Bosentan is a dual ET- 1 antagonist (i.e. it acts on both ETA and ETB receptors). Whether this action involves an effect on platelets remains to be established. In this review some of the studies describing the effect of ET-1 on human platelets are discussed. Vascular diseases where ET-1 is implicated are also considered.
Export Options
About this article
Cite this article as:
Jagroop Anita I., Daskalopoulou S. Stella and Mikhailidis P. Dimitri, Endothelin-1 and Human Platelets, Current Vascular Pharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157016105774329453
DOI https://dx.doi.org/10.2174/157016105774329453 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Circulating Microparticles as Therapeutic Targets in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Gene Therapy to Overcome Drug Resistance in Cancer: Targeting Key Regulators of the Apoptotic Pathway
Current Gene Therapy Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Diet, Cardiometabolic Factors and Type-2 Diabetes Mellitus: The Role of Genetics
Current Diabetes Reviews Therapeutic Strategies of Plant-derived Compounds for Diabetes Via Regulation of Monocyte Chemoattractant Protein-1
Current Medicinal Chemistry Probiotics and Oral Health
Current Pharmaceutical Design Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design EDITORIAL: Different Aspects of Early Vascular Aging in Hypertension
Current Hypertension Reviews Role of Polyphenols in Diet and Nutrition-An Updated Review
Current Nutrition & Food Science Podocytes as a Target of Insulin
Current Diabetes Reviews Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews Mitochondria as Targets for Neuronal Protection Against Excitotoxicity: A Role for Phenolic Compounds?
Central Nervous System Agents in Medicinal Chemistry IL-1 Cytokines in Cardiovascular Disease: Diagnostic, Prognostic and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research